FindTrial
Sign In

Implantable Microdevice (IMD)

COMBINATION_PRODUCT3 trials

Sponsors

Brigham and Women's Hospital, Oliver Jonas, Dana-Farber Cancer Institute

Conditions

Adenoid Cystic Carcinoma of the Salivary GlandBreast CancerBreast Cancer Stage IIBreast Cancer Stage IIIBreast CarcinomaBreast NeoplasmsEarly Stage Triple-Negative Breast CarcinomaHead and Neck Cancer

Early Phase 1

Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
RecruitingNCT05553782
Brigham and Women's HospitalAdenoid Cystic Carcinoma of the Salivary Gland, Head and Neck Cancer, Salivary Gland Cancer +1
Start: 2023-11-01End: 2029-08-01Target: 30Updated: 2026-01-26

Phase 1

Drug Screening Using Novel IMD in Renal Cell Carcinoma
RecruitingNCT05700461
Oliver JonasKidney Cancer, Metastatic Renal Cell Carcinoma, Renal Cell Carcinoma
Start: 2024-12-01End: 2029-08-31Target: 20Updated: 2026-05-18
Implantable Microdevice for TNBC - Pilot Study
WithdrawnNCT05774886
Dana-Farber Cancer InstituteBreast Cancer, Breast Cancer Stage II, Breast Cancer Stage III +4
Start: 2023-05-31End: 2028-09-01Updated: 2023-05-18

Related Papers

Abstract CT056: Phase I study of intratumoral microdevices reveals heterogenous immune and apoptotic responses across distinct drug-treated regions in adenoid cystic carcinoma of the head and neck
Cancer Research2026-04-17